Physician profile
Gregory A Echt
NPI 1689657298
$508.03
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $78.02 | 2019 | |
| Amgen INC. | $62.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.16 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $29.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.94 | 2019 | |
| Astellas Pharma US INC | $27.29 | 2019 | |
| Daiichi Sankyo INC. | $26.88 | 2019 | |
| Incyte Corporation | $26.52 | 2019 | |
| Dendreon Pharmaceuticals LLC | $21.79 | 2019 | |
| Eisai INC. | $21.46 | 2019 | |
| Heron Therapeutics, INC. | $20.13 | 2019 | |
| Genzyme Corporation | $19.08 | 2019 | |
| Celgene Corporation | $16.72 | 2019 | |
| Puma Biotechnology, INC. | $16.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.74 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $14.11 | 2019 | |
| Mylan Institutional INC. | $13.72 | 2019 | |
| Dova Pharmaceuticals | $13.42 | 2019 | |
| Lilly USA, LLC | $12.71 | 2019 | |
| Fortovia Therapeutics, INC. | $8.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Echt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.